SCHEMBL5567189

SCHEMBL5567189

Cc1ccc(C2=NN=C(N)C2)cc1

nearest known ligand 0.39

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 4/20 0.39
ALDH1A1 P00352 4/20 0.39
SMN1; SMN2 Q16637 4/20 0.39
MAPT P10636 3/20 0.39
NPC1 O15118 2/20 0.39
RAB9A P51151 2/20 0.39
PKM P14618 1/20 0.39
MAOB P27338 4/20 0.38
LMNA P02545 2/20 0.37
ACHE P22303 1/20 0.37
KDR P35968 1/20 0.36
XBP1 P17861 1/20 0.35
MAPK1 P28482 1/20 0.35
NPSR1 Q6W5P4 1/20 0.35
MAOA P21397 1/20 0.35
POLB P06746 1/20 0.35
KDM1A O60341 1/20 0.34
IKBKB O14920 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5021701 0.84 NPC1 (0.44) KDM4EALDH1A1SMN1; SMN2MAPTNPC1
SCHEMBL5566573 0.79 TDP1 (0.43) KDM4EALDH1A1SMN1; SMN2MAPTNPC1
SCHEMBL14016423 0.78 NPC1 (0.41) KDM4EALDH1A1SMN1; SMN2MAPTNPC1
SCHEMBL13910159 0.77 RAB9A (0.48) KDM4EALDH1A1SMN1; SMN2MAPTNPC1
SCHEMBL10330351 0.77 RAB9A (0.48) KDM4EALDH1A1SMN1; SMN2MAPTNPC1
SCHEMBL27491338 0.76 HRH3 (0.48) KDM4EALDH1A1SMN1; SMN2NPC1
SCHEMBL19075474 0.75 GAA (0.41) KDM4EALDH1A1SMN1; SMN2MAPTNPC1
SCHEMBL13910153 0.75 MAOB (0.47) KDM4EALDH1A1SMN1; SMN2MAPTNPC1
SCHEMBL21336168 0.72 NPC1 (0.37) KDM4EALDH1A1SMN1; SMN2MAPTNPC1
SCHEMBL21336154 0.68 NPC1 (0.42) KDM4EALDH1A1SMN1; SMN2MAPTNPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20170190698-A1 ENZYME INTERACTING AGENTS CENTRAL ADELAIDE LOCAL HEALTH NETWORK INCORPORATED (AU) 2017-07-06 US disclosed
US-7262201-B1 For the manufacture of a medicament for use in the production of an antiangiogenic and/or vascular permeability reducing effect in warm-blooded animals ASTRAZENECA AB (SE) 2007-08-28 US disclosed
EP-1119567-A1 QUINAZOLINE DERIVATIVES AstraZeneca AB (SE) 2001-08-01 EP disclosed
WO-2000021955-A1 QUINAZOLINE DERIVATIVES ASTRAZENECA AB (SE) 2000-04-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170190698-A1 ENZYME INTERACTING AGENTS SMPD1, SMPD2, ASAH1 KDM4E 3234/4885ALDH1A1 1318/4885SMN1; SMN2 3115/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.